THE USE OF VEP13 MONOCLONAL-ANTIBODY FOR DEFINITION OF NATURAL-KILLER CELLS - SPONTANEOUS KILLER CELLS DIRECTED AGAINST FRESH HUMAN-LEUKEMIA CELLS CARRY THE VEP13 ANTIGEN

Google Scholar
  • 1 January 1984
    • journal article
    • research article
    • Vol. 58  (2) , 470-477
Abstract
VEP13, an IgM monoclonal antibody (MoAb), produced against human large granular lymphocytes, is able to deplete natural killer (NK) cell activity in complement-dependent lysis. VEP13 also reacts with the majority of interferon (IFN) activated NK cells. Cytotoxic activity of unstimulated monocytes and cytotoxic T cells directed against allogeneic lymphocytes were unaffected by VEP13 plus complement treatment. Thus, among the major types of cytotoxic cells VEP13 selectively reacts with NK cells and hence can be employed to identify these cells. VEP13 was used in complement-dependent lysis and FACS [fluorescence-activated cell sorter] separation to analyze NK cells involved in enhanced killing of fresh leukemia cells. Spontaneous cell-mediated lysis of human leukemia cells was enhanced in 2 ways: effector cells were pre-treated with .beta.-IFN and leukemia cells were pretreated with a pulse of actinomycin D. In complement-dependent lysis VEP13 removed all NK cell activity of IFN activated peripheral blood monocytes against untreated and against ActD pretreated leukemia cells. FACS separation of VEP13 positive cells further supported this finding, in that all activity of IFN activated NK cells against actinomycin D pre-treated targets was found in the VEP13 positive fraction. Thus, enhanced killing of fresh human leukemia cells appears to be mediated VEP13 positive NK cells which are distinct from cytotoxic T cells and cytotoxic monocytes.

This publication has 19 references indexed in Scilit: